Blood Pressure Control and Inflammatory Markers in Type 2 Diabetic Patients Treated with Pioglitazone or Rosiglitazone and Metformin-Reference-Cited by-同舟云学术

Blood Pressure Control and Inflammatory Markers in Type 2 Diabetic Patients Treated with Pioglitazone or Rosiglitazone and Metformin

Published:2007 Issue:5 Volume:30 Page:387-394
ISSN:0916-9636
Container-title:Hypertension Research
language:en
Short-container-title:Hypertens Res

Author:

DEROSA Giuseppe,FOGARI Elena,CICERO Arrigo F. G.,D'ANGELO Angela,CICCARELLI Leonardina,PICCINNI Mario N.,PRICOLO Fabio,SALVADEO Sibilla A. T.,GRAVINA Alessia,FERRARI Ilaria,FOGARI Roberto

Publisher

Japanese Society of Hypertension

Subject

Cardiology and Cardiovascular Medicine,Physiology,Internal Medicine

Reference29 articles.

1. Diabetes and Atherosclerosis

2. 2. Clarke PM, Gray AM, Briggs A, Stevens RJ, Matthews DR, Holman R: Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia 2005; 48: 868-877.

3. 3. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: American Diabetes Association: Clinical practice recommendations 2002. Diabetes Care 2002; 25 (Suppl 1): S1-S147.

4. Improved glycaemic control by addition of glimepiride to metformin monotherapy in Type 2 diabetic patients

5. 5. Riddle M: Combining sulfonylureas and other oral agents. Am J Med 2000; 108 (Suppl 6a): 15S-22S.

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-inflammatory interventions to mitigate the cardiovascular risk in metabolic syndrome;Metabolic Syndrome;2024

2. Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug;Cardiovascular Diabetology;2021-05-18

3. Assessing the need for pioglitazone in the treatment of patients with type 2 diabetes: a meta-analysis of its risks and benefits from prospective trials;Scientific Reports;2020-09-25

4. Transcriptomic landscape profiling of metformin‐treated healthy mice: Implication for potential hypertension risk when prophylactically used;Journal of Cellular and Molecular Medicine;2020-06-11

5. Interplay between the renin-angiotensin system, the canonical WNT/β-catenin pathway and PPARγ in hypertension;Current Hypertension Reports;2018-06-09